Log in to search using one of your social media accounts:

 

Exogenous reproductive hormone use in breast cancer survivors and previvors.

Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol. 2018 Jan 23;: Authors: Vaz-Luis I, Partridge AH Abstract Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure for both previvors and survivors. We found these data to be hampered by small cohort sizes, heterogeneous patient populations, and limited study designs, highlighting a great need to conduct further research with the aim of enabling better-informed patient management. PMID: 29358778 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research

Related Links:

Exogenous reproductive hormone use in breast cancer survivors and previvors, Published online: 23 January 2018; doi:10.1038/nrclinonc.2017.207The safety of elective exogenous hormonal exposure among breast cancer survivors or women at high risk of having the disease has been debated for decades. Herein, the authors discuss the available data and present clinical recommendations regarding four areas of potential exogenous exposure to hormones: hormonal contraception; systemic hormone-replacement therapy; localized hormone-replacement therapy; and hormonal manipulation for fertility preservation or enhancement. Further resea...
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research
Conclusions:The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women. Newer trials will likely verify this assessment. If this is enough to change clinical practice, however, remains to be seen given the general fear of HT by many with prescriptive authority, and also the women in our care. Objective: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
ConclusionThe risk prediction model indicates that the following variables should be assessed in this specific population: age, height, having had previous breast biopsies, number of pregnancies, and use of hormone replacement therapy. These findings may help to better understand the causal model of breast cancer in Southern Brazil.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Abstract Insofar as altered estrogen receptor-progesterone receptor (PR) expression contribute to breast cancer pathogenesis, previous studies examined the association of genetic variation in PR gene (PGR) with breast cancer, but with mixed outcome. We evaluated the association between PGR variants, and breast cancer and associated features. A retrospective case-control study involving 183 female breast cancer patients, and 222 control women. PGR genotyping was done by real-time PCR. Minor allele frequencies of rs1042838, rs590688, and rs10895068 PGR gene polymorphisms were significantly higher in breast cancer pa...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
Conclusions: Female sex hormones are important for the preservation of lung function in middle aged women. The accelerated lung function decline with menopause is likely caused by decreasing estrogen levels.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Epidemiology Source Type: research
Vaginal oestrogen not linked to invasive breast cancer or pulmonary embolism risk.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
Breast cancer is the most frequent cancer among women especially in the Western world where, despite improved survival, it is one of the leading causes of death (1). Furthermore, for several decades there has been an increase in incidence, though recently there seems to be a stabilization in risk or even a small decline in typical high-risk areas such as Europe and the USA but at the same time a steep increase in typical low-risk societies such as Japan (2). Breast cancer is often regarded as a singular disease, but recent discoveries are pointing to a variety of types of potentially different etiology. Thus, the female...
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Editorial Source Type: research
MN, 50 years old, BMI: 36. Menopause was 7 years ago. No hormone replacement therapy before. She was treated for breast cancer and stopped using tamoxifen two years ago. Asymptomatic. She underwent to a screening transvaginal ultrasound that showed an endometrial thickness of 0.6  cm. Diagnostic hysteroscopy visualized two endometrial polyps. Surgical hysteroscopy was performed with The Integrated Bigatti Shaver (IBS®). The IBS® consists in a 6° angle telescope with an integrated sheath and a working channel in which a rigid shaver system is inserted.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Source Type: research
The unprecedented decline in breast cancer (BC) incidence in the US between 1999 and 2004 has been attributed to decreases in combined hormone replacement therapy (CHT) after Women ’s Health Initiative (WHI) study results in 2002 suggesting increased BC risk with CHT use. Questions remain about the plausibility of this explanation given long-term WHI data suggesting an attenuated association.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Scientific poster presentation Source Type: research
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormone Replacement Therapy | Hormones | Reproduction Medicine | Study | Women